From the *Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington; and †Duke University School of Medicine, Department of Biostatistics and Bioinformatics, Durham, North Carolina.
Anesth Analg. 2017 Mar;124(3):959-965. doi: 10.1213/ANE.0000000000001811.
Continuous peripheral nerve blocks offer advantages over single-injection blocks, including extended analgesia and reduction in opioid consumption. These benefits require that the perineural catheter remain intact for the duration of the planned local anesthetic infusion. Mechanical displacement of catheters, leaking, and consequent failure are known complications. The aim of this study was to evaluate continuous perineural catheter tip-to-nerve apposition in vivo over 48 hours comparing 2 different simple fixation strategies.
Subjects presenting for a continuous interscalene nerve block were randomized to perineural catheter fixation with 1 of 2 types of adhesive: Dermabond (2-octylcyanoacrylate) or Mastisol (alcohol 23A, gum mastic, storax, and methyl salicylate), covered with a simple transparent dressing. The primary outcome was the evaluation of catheter-to-nerve apposition maintenance over 48 hours via both a blinded ultrasound evaluation of local anesthetic distribution and a blinded clinical assessment. Secondary outcomes included leakage at the catheter site, pain scores, opioid consumption, catheter-to-skin migration at the insertion site, and patient satisfaction.
Sixty-six subjects were recruited and randomized to compare adhesive group catheter tip-to-nerve apposition on postoperative day 2 (POD 2). Within the intention-to-treat cohort, a statistically significant decrease of perineural catheter tip-to-nerve apposition in the Mastisol group (64.7%) compared with the Dermabond group (90.6%) on POD 2 (odds ratios [OR] 0.19; 95% confidence interval [CI] 0.05-0.75; P = .012) was observed. Similar results were observed on POD 1 (OR 0.19; 95% CI 0.03-1.38; P = NS) and POD 2 (OR 0.14; 95% CI 0.02-0.97; P = .008) within the as-treated cohort. Catheter leakage (OR 67; 95% CI 7.3-589) and median catheter migration difference at the skin insertion site (2.0 cm; 95% CI 0.5-2.5) were also significantly greater in the Mastisol group than in the Dermabond group from POD 0 to POD 2 (P < .001). Median postoperative opioid consumption difference in morphine equivalents (3.2 mg; 95% CI - 9.0 to 14.2) was not significantly different between the Dermabond and the Mastisol groups through POD 2 (P = .542).
Perineural catheter fixation with Dermabond in continuous interscalene nerve block improves maintenance of catheter-to-nerve apposition when compared with Mastisol.
与单次注射阻滞相比,连续外周神经阻滞具有延长镇痛和减少阿片类药物消耗等优势。这些益处要求神经周围导管在计划的局部麻醉输注期间保持完整。导管的机械移位、泄漏和随之而来的失败是已知的并发症。本研究的目的是评估在 48 小时内使用 2 种不同的简单固定策略,对连续肌间沟神经阻滞中连续神经周围导管尖端与神经的贴合情况进行评估。
接受连续肌间沟神经阻滞的患者被随机分为 2 组,每组使用 1 种不同的胶粘剂固定神经周围导管:Dermabond(2-辛基氰基丙烯酸酯)或 Mastisol(23A 酒精、树胶、苏合香脂和水杨酸甲酯),并用简单的透明敷料覆盖。主要结局是通过盲法超声评估局部麻醉剂分布和盲法临床评估评估 48 小时内导管与神经的贴合维持情况。次要结局包括导管部位渗漏、疼痛评分、阿片类药物消耗、导管插入部位与皮肤的迁移以及患者满意度。
共纳入 66 例患者,并随机比较术后第 2 天(POD 2)两种胶粘剂组导管尖端与神经的贴合情况。在意向治疗队列中,与 Dermabond 组(90.6%)相比,Mastisol 组(64.7%)在 POD 2 时神经周围导管尖端与神经的贴合明显减少(比值比[OR]0.19;95%置信区间[CI]0.05-0.75;P=0.012)。在治疗队列中,POD 1(OR 0.19;95% CI 0.03-1.38;P=NS)和 POD 2(OR 0.14;95% CI 0.02-0.97;P=0.008)也观察到类似的结果。与 Dermabond 组相比,Mastisol 组的导管渗漏(OR 67;95% CI 7.3-589)和皮肤插入部位导管迁移差异的中位数(2.0cm;95% CI 0.5-2.5)也显著更大,从 POD 0 到 POD 2(P<0.001)。POD 2 时,Dermabond 组和 Mastisol 组吗啡等效物的术后阿片类药物消耗差异中位数(3.2mg;95% CI-9.0 至 14.2)无显著差异(P=0.542)。
与 Mastisol 相比,连续肌间沟神经阻滞中使用 Dermabond 固定神经周围导管可改善导管与神经的贴合维持。